DK1021196T3 - Anvendelse af en kemisk stabiliseret chloritoplösning til inhibering af en antigenspecifik immunreaktion - Google Patents

Anvendelse af en kemisk stabiliseret chloritoplösning til inhibering af en antigenspecifik immunreaktion

Info

Publication number
DK1021196T3
DK1021196T3 DK98946681T DK98946681T DK1021196T3 DK 1021196 T3 DK1021196 T3 DK 1021196T3 DK 98946681 T DK98946681 T DK 98946681T DK 98946681 T DK98946681 T DK 98946681T DK 1021196 T3 DK1021196 T3 DK 1021196T3
Authority
DK
Denmark
Prior art keywords
chlorite solution
stabilized chlorite
antigen
immune response
inhibit
Prior art date
Application number
DK98946681T
Other languages
English (en)
Inventor
Frederich W Kuhne
Michael Mcgrath
Edgar G Engleman
Original Assignee
Oxo Chemie Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxo Chemie Ag filed Critical Oxo Chemie Ag
Application granted granted Critical
Publication of DK1021196T3 publication Critical patent/DK1021196T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK98946681T 1997-10-06 1998-10-06 Anvendelse af en kemisk stabiliseret chloritoplösning til inhibering af en antigenspecifik immunreaktion DK1021196T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6095397P 1997-10-06 1997-10-06
PCT/IB1998/001676 WO1999017787A2 (en) 1997-10-06 1998-10-06 Use of a chemically-stabilized chlorite solution for inhibiting an antigen-specific immune response

Publications (1)

Publication Number Publication Date
DK1021196T3 true DK1021196T3 (da) 2004-06-07

Family

ID=22032774

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98946681T DK1021196T3 (da) 1997-10-06 1998-10-06 Anvendelse af en kemisk stabiliseret chloritoplösning til inhibering af en antigenspecifik immunreaktion

Country Status (12)

Country Link
US (4) US20050129784A1 (da)
EP (1) EP1021196B1 (da)
JP (1) JP4369615B2 (da)
CN (1) CN1152691C (da)
AT (1) ATE258799T1 (da)
AU (1) AU754928B2 (da)
CA (1) CA2306273A1 (da)
DE (1) DE69821506T2 (da)
DK (1) DK1021196T3 (da)
ES (1) ES2217582T3 (da)
PT (1) PT1021196E (da)
WO (1) WO1999017787A2 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001012205A2 (en) * 1999-08-18 2001-02-22 Oxo Chemie Ag Chemically-stabilized chlorite solutions for treating cancer
AU2011205095B2 (en) * 2004-02-03 2014-07-03 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease
US7105183B2 (en) * 2004-02-03 2006-09-12 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease
JP5371443B2 (ja) 2005-12-22 2013-12-18 ニューラルタス ファーマシューティカルズ，インコーポレイテッド 亜塩素酸塩製剤、およびこの調製の方法と利用
EP2164502A1 (en) * 2007-06-01 2010-03-24 Dimethaid AG Use of wf10 for treating allergic asthma, allergic rhinitis and atopic dermatitis
JP2013501046A (ja) * 2009-08-06 2013-01-10 ニューラルタス ファーマシューティカルズ， インコーポレイテッド マクロファージ関連障害の処置
US9266957B2 (en) 2009-11-10 2016-02-23 Mayo Foundation For Medical Education And Research Methods and materials for treating renal cell carcinoma and glioblastoma multiforme
CA2857604A1 (en) 2011-12-22 2013-06-27 Nuvo Research Gmbh Liposomal chlorite or chlorate compositions
US20140356452A1 (en) * 2012-01-19 2014-12-04 Ibt Usa Inc. Therapeutic Uses of Tetrachlorodecaoxygen (TCDO)
US9970936B2 (en) 2012-11-13 2018-05-15 Mayo Foundation For Medical Education And Research Methods and materials for assessing immune system profiles
US10094835B2 (en) 2013-05-09 2018-10-09 Mayo Foundation For Medical Education And Research Treating patients based on immune subtypes
JP6900596B2 (ja) * 2015-08-20 2021-07-07 フリードリッヒ − ヴィルヘルム キューネ 赤血球疾患およびそれによって媒介される症状を治療するための亜塩素酸塩の使用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4574084A (en) * 1983-02-25 1986-03-04 Peter Berger Process for the preparation of a modified aqueous chlorite solution, the solution prepared by this process and the use thereof
DE3515749A1 (de) * 1985-05-02 1986-11-06 Oxo Chemie GmbH, 6900 Heidelberg Verwendung einer stabilisierten chloritmatrixloesung bei infektioesen zustaenden
DE3515745A1 (de) * 1985-05-02 1986-11-06 Oxo Chemie GmbH, 6900 Heidelberg Waessrige chloritmatrix-loesung
US4851222A (en) * 1988-01-27 1989-07-25 Oxo Chemie Gmbh Method of promoting regeneration of bone marrow
US4956184A (en) * 1988-05-06 1990-09-11 Alcide Corporation Topical treatment of genital herpes lesions
DE4208828A1 (de) * 1992-03-19 1993-09-23 Oxo Chemie Gmbh Verwendung einer chemisch stabilisierten chloritmatrix zur herstellung von arzneimitteln zur behandlung von hiv-infektionen
US5830511A (en) * 1992-06-25 1998-11-03 Bioxy Inc. Therapeutic, production and immunostimulatory uses of biocidal compositions
US5877222A (en) * 1996-07-19 1999-03-02 The Regents Of The University Of California Method for treating aids-associated dementia
EP2164502A1 (en) * 2007-06-01 2010-03-24 Dimethaid AG Use of wf10 for treating allergic asthma, allergic rhinitis and atopic dermatitis

Also Published As

Publication number Publication date
US20120141514A1 (en) 2012-06-07
US20050129784A1 (en) 2005-06-16
AU9364298A (en) 1999-04-27
PT1021196E (pt) 2004-06-30
US20090004295A1 (en) 2009-01-01
JP2001518512A (ja) 2001-10-16
WO1999017787A3 (en) 1999-06-17
ATE258799T1 (de) 2004-02-15
US20110076344A1 (en) 2011-03-31
CN1306433A (zh) 2001-08-01
DE69821506D1 (de) 2004-03-11
WO1999017787A2 (en) 1999-04-15
AU754928B2 (en) 2002-11-28
CA2306273A1 (en) 1999-04-15
EP1021196A2 (en) 2000-07-26
JP4369615B2 (ja) 2009-11-25
EP1021196B1 (en) 2004-02-04
DE69821506T2 (de) 2004-12-16
ES2217582T3 (es) 2004-11-01
CN1152691C (zh) 2004-06-09

Similar Documents

Publication Publication Date Title
Bloom et al. Selective primary health care: strategies for control of disease in the developing world. V. Leprosy
Stacey et al. Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major
IL132468A0 (en) A kit for inducing immune response against a tumor or a disease caused by an infection agent
Ninnemann et al. Prolonged survival of human skin allografts following thermal injury
DK1021196T3 (da) Anvendelse af en kemisk stabiliseret chloritoplösning til inhibering af en antigenspecifik immunreaktion
DE69637942D1 (de) Stimulationsfaktor für dendriten
DE69939747D1 (de) Verfahren von dna-impfung
DK0666760T4 (da) Vaccine som omfatter en del af den konstante region af IgE til behandling af IgE-medierede allergiske reaktioner
DK0714444T3 (da) Dæmpning af en immundominant epitop i et antigen til anvendelse i plante-, dyre- og humanvacciner og immunbehandlinger
DE69231837T8 (de) Antigen praesentierende ms2-huelle
DK1003552T3 (da) LO-CD2a-antistof og anvendelser deraf til inhibering af T-celle-aktivering og -proliferation
FI924082A0 (fi) Idiotypvaccination mot b-cellymfoma.
Safai et al. Immunodermatology
Waksman et al. Lymphocytic functions acted on by immunoregulatory cytokines significance of the cell cycle
WAKSMAN Overview: Biology of the lymphokines
DK0687300T3 (da) LO-CD2a-antistof og anvendelser deraf til inhibering af T-celle-aktivering og -proliferation
Belehu et al. Immunopathological aspects of leishmaniasis
KR930019225A (ko) 제암방법 및 제암제
Mitchison T cells in transplantation immunity
DE69835615D1 (de) Induzierte zelluläre immunitität durch aktivierung der th1 und unterdrückung der th2 antwort durch macrophhagen
BR9808878A (pt) Imunização contra moléculas endógenas
Micali An Autoimmune Mechanism for AIDS'T4 Lymphopenia
Miura et al. Immunity to jellyfish venoms: suppression of venom-induced immune responses in ultraviolet B-irradiated mice
Haubeck et al. Analysis of T suppressor cell-mediated tumor escape mechanisms is facilitated by the selective in vitro activation of tumor-specific Ts cells
Halle-Pannenko et al. Use of soluble histocompatibility antigen (s) in the control of transplantation reactions: possible dissociation of the roles of H-2 and non-H-2 antigens in the prevention of mortality induced by graft-versus-host reaction